Literature DB >> 404132

The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer.

A M Brodie, W C Schwarzel, A A Shaikh, H J Brodie.   

Abstract

4-Hydroxy-f-androstene-3,17-dione (4-OH-A) when tested at various concentrations was found to inhibit markedly the conversion of 4-andorstene-3,17-dione to estrogens inhuman placental and rat ovarian microsomes. To obtain evidence that estrogen biosynthesis could also be reduced in vivo with 4-OH-A, rats were treated sc at a dose level of 50 mg/kg body weight. After 3 h the ovarian veins were cannulated and blood collected. Estradiol concentrations in the plasma were reduced by 80% compared to control values during the proestrous surge and on Day 4 of pregnancy. 4-OH-A was also found to be effective in controlling estrogen-dependent reproductive and neoplastic processes. In rats treated from Day 2-7 of pregnancy, implantation of fertilized ova was completely prevented in some rats, while in others either implantation was delayed or the development of implants was retarded. 4-OH-A treatment of rats having estrogen-dependent breast tumors induced by 7,12-dimethylbenz(a)anthracene caused 80% of the tumors to regress significantly in 4 weeks of treatment; 42% of these regressed completely.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 404132     DOI: 10.1210/endo-100-6-1684

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  42 in total

Review 1.  Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.

Authors:  Debashis Ghosh; Jessica Lo; Chinaza Egbuta
Journal:  J Med Chem       Date:  2016-01-19       Impact factor: 7.446

2.  Angela M. Hartley Brodie (1934-2017).

Authors:  Balkees Abderrahman; V Craig Jordan
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

3.  Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells.

Authors:  C J Corbin; S Graham-Lorence; M McPhaul; J I Mason; C R Mendelson; E R Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 4.  Recent advances in studies on estrogen biosynthesis.

Authors:  A M Brodie
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

5.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

Review 6.  Aromatase inhibitors in the treatment of postmenopausal breast cancer.

Authors:  E Bajetta; N Zilembo; E Bichisao
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

7.  Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.

Authors:  T Zaccheo; E Di Salle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  DDE-induced changes in aromatase activity in endometrial stromal cells in culture.

Authors:  Alison C Holloway; Katie A Stys; Warren G Foster
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

Review 9.  Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

10.  Inhibition of growth and appearance of estrogen-dependent rat mammary tumors by 10-propargylestr-4-ene-3,17-dione, an aromatase inhibitor.

Authors:  S J Zimniski; M E Brandt; D F Covey; D Puett
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.